Danaher Corp (DHR) reports robust Q3 performance with $6.1 billion in sales, a 10% increase in adjusted EPS, and a $2 billion ...

Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion and non-GAAP adjusted EPS of $1.89, significantly ...

I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing ...

Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3 ...

Danaher Corporation DHR is scheduled to release second-quarter 2023 results on Jul 25, before market open. The Zacks Consensus Estimate for the company’s second-quarter earnings has been revised ...